RETRACTED: The clinical evaluation of combined detection of microcirculation, lipid metabolism, and inflammatory-related factors in the treatment of diabetic nephropathy with atorvastatin

RETRACTED: The clinical evaluation of combined detection of microcirculation, lipid metabolism, and inflammatory-related factors in the treatment of diabetic nephropathy with atorvastatin

Saved in:

Bibliographic Details
Main Authors:	Haicheng Wang, Zhengfang Zhang, Jiali Sun
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-04-01
Series:	European Journal of Inflammation
Online Access:	https://doi.org/10.1177/2058739219847830
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

RETRACTED: Effects of combined use of atorvastatin and losartan in treating patients with diabetic nephropathy
by: Chao Ding, et al.
Published: (2018-10-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

FEATURES MICROCIRCULATION MOUTH WITH INFLAMMATORY-DESTRUCTIVE DISEASES
by: D. V. Mihalchenko, et al.
Published: (2016-08-01)

Lipid and pleiotropic effects of atorvastatin in patients with acute coronary syndrome
by: A. A. Yalymov, et al.
Published: (1970-01-01)

Lipid and pleiotropic effects of atorvastatin in patients with high cardiovascular risk
by: R. S. Karpov, et al.
Published: (2009-08-01)

RETRACTED ARTICLE: Association of the polymorphisms in FOXO1 gene and diabetic nephropathy risk
by: Jianxia Ma, et al.
Published: (2019-12-01)

High-Dose Atorvastatin Raises Threshold of Contrast-Induced Nephropathy in Diabetic Patients Undergoing Elective Coronary Intervention: A Randomized Controlled Study
by: Ahmed Abdel-Galeel, et al.
Published: (2021-01-01)

Microcirculation
by: Michael Piagnerelli, et al.
Published: (2012-01-01)

An Overview of Diabetic Nephropathy
by: Alp Atasoy, et al.
Published: (2015-03-01)

Effects of the combined use of atorvastatin and curcetin on inflammatory biomarkers in patients with unstable angina after COVID-19 (“Long COVID”)
by: R. B. Alieva, et al.
Published: (2023-03-01)

Lipid-lowering effectiveness of a Russian generic of atorvastatin in patients with various hyperlipidaemia phenotypes
by: P. P. Malyshev, et al.
Published: (2009-12-01)

Epigenetic Regulations in Diabetic Nephropathy
by: Zeyuan Lu, et al.
Published: (2017-01-01)

ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE
by: M. V. Solodun, et al.
Published: (2015-09-01)

Risk factors of diabetic nephropathy with retinopathy
by: Liang Dong-rui, et al.
Published: (2022-05-01)

Comprehensive Mendelian randomization analysis of inflammatory networks in diabetic nephropathy and pituitary adenoma: unveiling complex causal relationships
by: Yi Fu, et al.
Published: (2025-08-01)

Lipid metabolism correction in elderly patients with Type 2 diabetes mellitus
by: L. G. Gonokhova
Published: (2006-08-01)

Roles of lactylation in lipid metabolism and related diseases
by: Bing Zhao, et al.
Published: (2025-08-01)

Analysis of diabetic nephropathy in type 2 diabetes mellitus and prediabetes
by: T. A. Garkusha, et al.
Published: (2024-01-01)

Cognitive status and influencing factors of diabetic nephropathy in diabetic population
by: Zhu Hong-zhe, et al.
Published: (2022-11-01)

The care of the elderly with diabetic nephropathy in conservative treatment
by: Caren da Silva Jacobi, et al.
Published: (2013-08-01)

Be Alert to Diabetes Nephropathy with Cognitive Dysfunction [Letter]
by: Gan L, et al.
Published: (2024-11-01)

Advances in application of ultrasound in diagnosis of diabetic nephropathy
by: GUO Juan, YANG Zhifang, JI Ri
Published: (2025-06-01)

Association of Serum Adropin Concentrations with Diabetic Nephropathy
by: Wenchao Hu, et al.
Published: (2016-01-01)

RETRACTED: Correlation of serum CF6 with blood lipid and glucose in patients with type 2 diabetic retinopathy
by: Xiaoling Yan, et al.
Published: (2019-05-01)

Abnormal Microcirculation and Red Blood Cell Function as a Cardiovascular Risk Factor in Metabolic Syndrome
by: V. I. Podzolkov, et al.
Published: (2018-09-01)

Conservative therapy of epidural hematoma with atorvastatin combined with glucocorticoids: cases report and literature review
by: Chenrui Wu, et al.
Published: (2025-04-01)

Network pharmacological investigation and experimental verification of the peel of Zea mays L. regulating metabolic reprogramming in the treatment of diabetic nephropathy
by: Andong Wang, et al.
Published: (2025-07-01)

Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy
by: Jianzhong Chen, et al.
Published: (2017-01-01)

Development and validation of a predictive nomogram for differentiating diabetic nephropathy from non-diabetic nephropathy in patients with T2DM: a multicenter study
by: Zishan Lin, et al.
Published: (2025-06-01)

Natural substance rutin versus standard drug atorvastatin in a treatment of metabolic syndrome-like condition
by: Dominika Micháliková, et al.
Published: (2019-12-01)

EFFECTS OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION IN TYPE 2 DIABETIC PATIENTS WITH DIFFERENT DURATION F THE DISEASE
by: G. A. Batrak, et al.
Published: (2015-09-01)

ATORVASTATIN — 20 YEARS IN THE STRUGGLE FOR LIFE
by: N. G. Gogolashvili
Published: (2018-03-01)

Identification and experimental validation of mitochondrial and endoplasmic reticulum stress related gene in diabetic nephropathy
by: Ting Li, et al.
Published: (2025-08-01)

Regulation of Lipid Metabolism and Beyond
by: Youngah Jo, et al.
Published: (2016-01-01)

Taurine Alleviates the Progression of Diabetic Nephropathy in Type 2 Diabetic Rat Model
by: Jang Hyun Koh, et al.
Published: (2014-01-01)

EFFECTS OF MILDRONATE, AS A PART OF COMBINED HEART FAILURE THERAPY, ON CARBOHYDRATE AND LIPID METABOLISM AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2010-04-01)

Lipid metabolism-related inflammatory indices (LMIIs) and incident peripheral artery diseases (PAD) in patients with type 2 diabetes mellitus (T2DM): a multicohort study from China and the UK biobank
by: Yingying Wang, et al.
Published: (2025-08-01)

Correction of endothelial dysfunction and microcirculation disturbances in patients with essential arterial hypertension and Type 2 diabetes mellitus
by: N. V. Yakutina
Published: (2007-12-01)

DF-5 COMPOUND DELAYS DEVELOPMENT OF DIABETIC NEPHROPATHY IN RATS
by: A. A. Spasov, et al.
Published: (2023-02-01)

Proteases and Protease Inhibitors of Urinary Extracellular Vesicles in Diabetic Nephropathy
by: Luca Musante, et al.
Published: (2015-01-01)